CORDIS · 947081 · H2020
BRONCHOTHELIN The first-in-class disease-modifying drug for chronic airway disorders
Coordinator: EpiEndo Pharmaceuticals ehf (IS)
EpiEndo Pharmaceuticals is a drug development company focused on developing novel drugs that target epithelial differentiation and enhance regeneration and barrier function. In contrast to the prevailing anti-inflammatory approach to respiratory drug discovery, EpiEndo has come up with a novel paradigm-changing platform to develop drug candidates that alter (respiratory) epithelial stem cell differentiation and enhance epithelial regeneration of the airway epithelium.By rational design we have discovered and developed Bronchothelin, is the first-in-class disease-modifying treatment for Chroni…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €2.5M toward a total project budget of €3.6M — a funding rate of 70%, with the remainder covered by the consortium partners. The project runs over approximately 2 years from 2020-01-01 to 2021-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from IS
see all →- WHISPER — Wind Energy Harvesting for Ship Propulsion Assistance and Power101096577 · HORIZON · €9.0M
- MarineGuardian — Advancing Sustainable Fisheries and Marine Ecosystem Conservation in the Atlantic and Arctic Sea basin101212608 · HORIZON · €8.0M
- BioProtect — ADVANCING AREA-BASED MANAGEMENT TOOLS TO ACCELERATE THE PROTECTION AND RESTORATION OF MARINE BIODIVERSITY ACROSS THE EUROPEAN SEA BASINS101157341 · HORIZON · €8.0M
- FUTUREVOLC — A European volcanological supersite in Iceland: a monitoring system and network for the future308377 · FP7 · €6.0M
- FarFish — Responsive Results-Based Management and capacity building for EU Sustainable Fisheries Partnership Agreement- and international waters727891 · H2020 · €5.0M
- LIBBIO — Lupinus mutabilis for Increased Biomass from marginal lands and value for BIOrefineries720726 · H2020 · €4.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the SME-2b funding scheme.
- What is the EU contribution?
- The European Commission contributes €2.5M toward a total project budget of €3.6M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-EIC-SMEInst-2018-2020.
- Who coordinates the project?
- The project is coordinated by EpiEndo Pharmaceuticals ehf (IS).
- What is the project timeline?
- The project runs from 2020-01-01 to 2021-12-31 — approximately 2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 947081.